Want to see NBP full AI Analyst Report?
NBP Stock Chart & Stats
$1.98
$0.05(2.94%)
At close: 4:00 PM EDT
$1.98
$0.05(2.94%)
Day’s Range― - ―
52-Week Range$1.46 - $6.79
Previous Close$1.79
Volume178.26K
Average Volume (3M)613.91K
Market Cap
$228.46M
Enterprise Value$251.44
Total Cash (Recent Filing)$30.14M
Total Debt (Recent Filing)$438.46K
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding115,381,690
10 Day Avg. Volume302,898
30 Day Avg. Volume613,909
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-8.04
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside354.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And Debt-free Balance SheetThe sizable cash position and absence of debt provide financial flexibility to fund near-term clinical milestones, reduce solvency risk, and support development through important oncology and ophthalmology readouts.
Givastomig Clinical And Regulatory ProgressFast Track status, supportive FDA feedback, and advancement into randomized development improve the lead program’s regulatory positioning and could accelerate commercialization if efficacy is confirmed in later-stage trials.
Diversified Late-stage PipelineProgress in VIS-101 gives NovaBridge a second clinical value driver beyond oncology. Positive visual and safety results, followed by planned Phase IIb development, broaden potential partnering and future revenue opportunities.
Bears Say
Persistent Losses And Minimal RevenueNovaBridge lacks a stable revenue base and remains materially unprofitable. Continued reliance on clinical success before commercialization leaves fundamentals vulnerable to trial delays, setbacks, and prolonged operating losses.
Ongoing Cash Burn And Financing DependencyMulti-year negative cash flow means the current cash balance is not self-replenishing. Funding pivotal trials may require capital raises, partnerships, or transactions, creating execution risk and potential shareholder dilution.
Competitive And Regulatory UncertaintyMultiple competing CLDN18.2 approaches could make differentiation and commercial adoption harder. Uncertainty around the PD-L1-negative population also narrows or complicates the potential label and development strategy.
NovaBridge Biosciences News
NBP FAQ
What was NovaBridge Biosciences’s price range in the past 12 months?
NovaBridge Biosciences lowest stock price was $1.46 and its highest was $6.79 in the past 12 months.
What is NovaBridge Biosciences’s market cap?
NovaBridge Biosciences’s market cap is $228.46M.
When is NovaBridge Biosciences’s upcoming earnings report date?
NovaBridge Biosciences’s upcoming earnings report date is Mar 31, 2027 which is in 222 days.
How were NovaBridge Biosciences’s earnings last quarter?
NovaBridge Biosciences released its earnings results on Aug 20, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.02.
Is NovaBridge Biosciences overvalued?
According to Wall Street analysts NovaBridge Biosciences’s price is currently Undervalued.
Does NovaBridge Biosciences pay dividends?
NovaBridge Biosciences does not currently pay dividends.
What is NovaBridge Biosciences’s EPS estimate?
NovaBridge Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NovaBridge Biosciences have?
NovaBridge Biosciences has 115,381,690 shares outstanding.
What happened to NovaBridge Biosciences’s price movement after its last earnings report?
NovaBridge Biosciences reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went down -3.535%.
Which hedge fund is a major shareholder of NovaBridge Biosciences?
Currently, no hedge funds are holding shares in NBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovaBridge Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (354.55% Upside)
$9.00 (354.55% Upside)
Blogger Sentiment
Bullish
NBP Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 350.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $23.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Company Description
NovaBridge Biosciences
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
NBP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong clinical and regulatory progress—most notably for givastomig (Fast Track designation, FDA Type B guidance, robust Phase Ib signals) and positive topline VIS-101 Phase IIa results—backed by a solid cash position and a debt-free balance sheet with runway through a 2028 Phase III interim readout. However, key execution risks remain: Phase III initiation is contingent on additional financing, the CLDN18.2 competitive landscape is intensifying, PD-L1 negative population strategy is unresolved, and the Visara ophthalmology path will likely require significant capital (and may dilute shareholders). Overall, the positives (clear clinical momentum, regulatory endorsements, and a healthy balance sheet) outweigh the operational and financing uncertainties, yielding cautious optimism but with notable execution risks.View all NBP earnings summariesNBP Stock 12 Month Forecast
Average Price Target
$9.00
▲(354.55% Upside)
Ownership Overview
0.62% Insiders
0.07% Mutual Funds
13.22% Other Institutional Investors
84.90% Public Companies and
Individual Investors